Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Steven John

NIH director talks about the organization and cystic fibrosis conference

Go Deeper.

Create an account or log in to save stories.

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

The 23rd annual North American Cystic Fibrosis Conference is taking place in Minneapolis this weekend. More than 3,000 leading scientists and health care workers from around the world have gathered to talk about the latest treatment and research into the chronic lung disease.

A pioneer in Cystic Fibrosis research, Dr. Francis Collins, opened the conference last night. Collins was part of the team that 20 years ago, discovered the gene that causes CF.

Today, he is better known as the director of the National Institutes of Health - the biomedical research arm of the federal government.

President Obama called him "one of the top scientists in the world," when he nominated Collins to the post in June.

Dr. Collins talked with All Things Considered about cystic fibrosis and some of his other priorities in his new post at NIH.